Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy of GVGH Shigella Sonnei Vaccine (1790GAHB) in Challenge Study
NCT03527173Phase 2Completed
- Sponsor
- GSK
- Start
- Aug 2018
- Primary completion
- May 2019
- Modality
- Lipid-based Nanoparticles, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of meningococcal group B fHbp recombinant vaccine in shigellosis (2 arms), sponsored by GSK. Primary endpoint: Percentage of Subjects With at Least One Episode of Shigellosis According to the Protocol Primary Case Definition. Started Aug 2018; status: completed.
02
Drugs
meningococcal group B fHbp recombinant vaccine
03
Conditions
shigellosis
Beyond the preview
Go deeper on NCT03527173.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03527173.